Recce Ltd has released a press release.
Expansion and Acceleration of Clinical Programs
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Appendix 4E
- Phase I Clinical Trial of R327 I.V. - 6000mg Complete
- Corporate Presentation - Aussie Equities Day 2022
- Phase I Positive Safety Data - 4000mg Complete
- Phase I Clinical Trial R327 Advances to 4000mg
Later from Recce Pharmaceuticals
- R327 COVID Study Update
- Pause in trading
- Anti-Infective Portfolio Update and Webinar details
- Approval to Start Phase I/II Diabetic Foot Ulcer Study
- Anti-Infective Research Unit est. at Murdoch Childrens
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals